arrow
H

Hiroshi Tanaka

Aichi Cancer Center
H指数:58
被引数:1.6万
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC)

TASUKI-52的通俗摘要:一项研究观察纳武利尤单抗联合铂类化疗和贝伐珠单抗作为晚期或复发性非鳞非小细胞肺癌(NSCLC)患者联合治疗的临床研究

2026-02-010
OA
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52

Nivolumab联合化疗和贝伐单抗治疗TASUKI-52非鳞NSCLC患者的4年预后

2026-01-290
OAAI
Clinicopathological Analysis of Immunologically High-Risk Kidney Transplantation Using High-Dose Intravenous Immunoglobulin as Desensitization Therapy

应用大剂量静脉免疫球蛋白作为去致敏疗法的免疫高风险肾移植的临床病理分析

NEPHRON
IF1.8
2025-09-010
PRE
1664: Combination of LUNA18, a novel RAS inhibitor, with KRAS G12C inhibitors augments anti-tumor activity via inhibition of MAPK pathway reactivation

1664: 新型RAS抑制剂LUNA18与KRAS G12C抑制剂联合应用可通过抑制MAPK通路再激活增强抗肿瘤活性

2024-03-220
PRE